Medtronic (MDT)

Medtronic remains a dependable dividend aristocrat, but its long-term total shareholder returns lag significantly behind peers like Johnson & Johnson and Stryker. Despite a solid 2025 performance, the...

Medtronic plc MDT announced on May 21 its plans to separate its Diabetes business into a separate, publicly traded company. The separation will occur via a two step transaction – an initial minority I...

The S&P 500 index (^GSPC 0.38%) is offering a minuscule 1.2% average yield today. That's not much to support a dividend-focused investor's income needs and speaks to a market that is richly valued.

Several years ago I bought shares of 3M (MMM -1.73%) even though it was in the middle of a major class-action lawsuit. I believed the industrial giant would survive the legal issues, which it has.

Medtronic (MDT 0.54%) is a large medical device maker, but its stock hasn't performed particularly well of late. After hitting a peak in 2021, the stock fell nearly 50% and has since moved roughly sid...

Volatility is a part of life for long-term investors. The reasons the market goes up or down change, but the constant is that high-quality stocks, businesses that increasingly make more money over tim...

Deal OverviewOn May 21, 2025, Medtronic plc (NYSE: MDT; $87.44, Market Capitalization: $112.1 billion), a global leader in medical technology, announced its intent to spin off its Diabetes business in...

Medtronic (MDT 0.12%) is a medical device company with vast and diverse operations. Its business is fairly stable although the stock's returns haven't been all that great.

The market continues to chase growth while ignoring once beloved income stocks. Verizon offers a compelling 6.3% dividend yield, robust free cash flow, and trades well below its historical valuation, ...

Over the past few years, Medtronic (MDT 0.80%) has faced significant challenges, including a pandemic-induced slowdown, relatively slow revenue growth, and economic issues that impacted its financial ...